Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential

Published Date: October 2009 Published By: Datamonitor Page Count: 265 Order Code: R313-55070 $15,200.00   Online Download $38,000.00   Global Site License   Questions About This Report E-mail a Colleague Printable Page Fax Your Order Description Table of Contents Similar Products Introduction In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase the barrier to entry for prospective players, although viable commercial opportunities exist to optimize returns from this lucrative drug class market Scope In-depth analysis of the current and future anticonvulsant drug class market across the US, Japan, France, Germany, Italy, Spain and the UK. Country-specific total brand sales forecasts for key products, generics and pipeline agents across the seven major markets to 2018. Assessment of the main opportunities and threats present in the anticonvulsant market, with analysis of trends in emerging markets. Evaluation of the indication expansion strategies employed by leading anticonvulsant players, such as Pfizer, GlaxoSmithKline, and Johnson & Johnson. Highlights Bipolar disorders, migraine prophylaxis, fibromyalgia and neuropathic pain represent the most attractive indication expansion opportunities for anticonvulsant developers, providing blockbuster revenues. Strong growth in non-epilepsy conditions will see Pfizer's Lyrica (pregabalin) become the market leading brand by 2018. Several leading anticonvulsant brands have reached the end of their lifecycle in the US and EU. In an attempt to offset revenue decline, marketers are looking towards geographical expansions. Due to reduced competition, Japan represents an attractive market as are emerging markets. UCB's Keppra's (levetiracetam) is the leading treatment for epilepsy. Despite the recent launch of two further anticonvulsants and the presence of a late-stage pipeline candidate, generic erosion of Keppra will cause UCB's position in the anticonvulsant market to decline between 2009 and 2018. Reasons to Purchase Quantify the performance of key marketed and pipeline anticonvulsant drugs in the seven major markets over the period 2008 to 2018. Assess the changing key opportunities and threats affecting current market players and prospective new entrants. Identify the leading brands in this drug class over the next 10 years and understand the key factors driving their success. Please note: this is delivered as a Zip file. Similar Products • Snapshots US Pharmaceuticals 2009 Published Nov 2009 by Snapdata International Group • Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis Published Nov 2009 by Aruvian's R'search • Pharmaceutical Industry in Mexico Published Nov 2009 by Aruvian's R'search • Pharmaceuticals Industry Report Published Nov 2009 by Plimsoll Publishing Ltd. • Antipsychotics Market Forecast Published Oct 2009 by Datamonitor • Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes Published Oct 2009 by Datamonitor • Prescription Drug Wholesaling in the US - Industry Risk Rating Report Published Oct 2009 by IBISWorld • Antidepressants Market Forecast Published Oct 2009 by Datamonitor • Snapshots Bulgaria Pharmaceuticals 2009 Published Oct 2009 by Snapdata International Group • Snapshots Australia Pharmaceuticals 2009 Published Oct 2009 by Snapdata International Group